Rationale for Immune Checkpoint Inhibitors and Optimizing Treatments for Recurrent or Metastatic HNSCC

Download these slides from a CCO symposium in Austin discussing the rationale for checkpoint inhibition in advanced HNSCC, practical guidance on clinical use, and promising near-future immunotherapies for HNSCC.
Barbara Burtness, MD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
Released: May 1, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck & Co., Inc.

Related Content

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
person default Saad A. Khan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023

Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH
Program Director
Yelena Y. Janjigian, MD Sandip P. Patel, MD
Released: June 8, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings